Immunotherapy for chronic myelocytic leukemia
CA 2418014 C · Owner: Immunomedics, Inc. · Inventors: Hansen, Hans J.; Goldenberg, David M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Immunotherapy utilizing naked anti-granulocyte antibodies provides an effective means for treating chronic myelocytic leukemia (CML). Such antibodies can be administered alone or in combination with other therapies such as immunoconjugates or chemotherapeutics. In either format an effective , therapy for treating CML is provided which avoids the toxic side-effects , typically associated with cancer therapy. The disclosed immunotherapy also is effective for treating acute myelocytic leukemia (AML) when coadministered with inducing agents which induce expression of antigens minimally displayed on the surface of myeloblasts.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 8, 2001 and granted January 21, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 8, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 8, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.